EUCTR2006-000977-31-IT进行中（未招募）1 期
PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE ORENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNETOLERANT PHASE - STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female patients 3 to less than 18 years of age at baseline (12– 17 years of age at baseline in Russia)
- •Positive for HBsAg and HBeAg for more than 6 months prior to baseline
- •Detectable HBV-DNA (> 10,000 copies/mL [> 2000 IU/mL]) (as measured by PCR or hybridization) on at least 2 occasions at least one month apart with the latest determination obtained = 42 days prior to
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will be excluded.
研究者
相似试验
进行中（未招募）
1 期
A Study of Pegasys in Combination with antiviral HBV oral Lamivudine or entecavir compared against no treatment in Children Positive buttolerant to Chronic Hepatitis B.EUCTR2006-000977-31-GBF. Hoffmann-La Roche Ltd114
进行中（未招募）
1 期
A Study of Pegasys in Combination with antiviral HBV oral Lamivudine or entecavir compared against no treatment in Children Positive buttolerant to Chronic Hepatitis B.Chronic Hepatitis B Virus infectionMedDRA version: 20.0Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)System Organ Class: 100000004848EUCTR2006-000977-31-BEF. Hoffmann-La Roche Ltd59
进行中（未招募）
1 期
A Study of Pegasys in Combination with antiviral HBV oral Lamivudine or Entecavir compared against no treatment in Children Positive but tolerant to Chronic Hepatitis B.Chronic Hepatitis B Virus infectionMedDRA version: 20.0Level: LLTClassification code 10019743Term: Hepatitis B virus (HBV)System Organ Class: 100000004848EUCTR2006-000977-31-DEF. Hoffmann-La Roche Ltd59
招募中
不适用
A PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF DOLUTEGRAVIR OR EFAVIRENZ EACH ADMINISTERED WITH TWO NRTIS IN HIV-1-INFECTED ANTIRETROVIRAL THERAPY-NAÏVE ADULTS STARTING TREATMENT FOR RIFAMPICIN-SENSITIVE TUBERCULOSISPER-069-14ViiV Healthcare UK Limited,14
尚未招募
3 期
Study of Pegylated interferon alfa-2a in combination with Lamivudine or Entecavir in children with Chronic Hepatitis BCTRI/2017/07/009027F HoffmannLa Roche Ltd114